Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXL01 and Nivolumab in Advanced NSCLC
NCT06448572Phase 2Recruiting
- Sponsor
- CHU de Lille
- Start
- Jul 2024
- Primary completion
- Oct 2028
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of exl01 in non-small cell lung cancer (NSCLC), sponsored by CHU de Lille. Primary endpoint: Progression-Free Survival Rate at 3 months. Started Jul 2024; status: recruiting.
02
Drugs
exl01
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06448572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06448572.